no consistent signal for organ toxicity or long-term harm across decades of use Special Populations: Clinical experience exists in elderly patients with dementia and stroke patients, populations where safety data is particularly valuable IV Administration Considerations: Requires clinical administration setting for intravenous dosing, which limits convenience but ensures medical oversight Dihexa: Unknown Human Safety Profile Dihexa has never been administered to humans in any controlled setting, creating a complete absence of human safety data: No Human Pharmacokinetics: Absorption, distribution, metabolism, and excretion parameters are unknown in humans Theoretical c-Met Oncogenesis Concern: The c-Met/HGF pathway is implicated in cancer progression aberrant c-Met signaling promotes tumor growth, metastasis, and angiogenesis in multiple cancer types
It is currently classified as a research peptide and has not been evaluated by the FDA for safety or efficacy in humans
Cyano is a man-made form of vitamin B12. It is used to prevent and to treat vitamin B12 deficiency
Clinical Status Human RCT | Observational | Animal | In vitro Primarily studied in preclinical and exploratory neurophysiological research contexts, with limited controlled human trials
Enhanced Pharma tests this per batch
Quality issues occasionally emerge
